HCIL Hongchang International (HCIL) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001086303
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about HCIL
Insiders, 180 days
-$1.8K net sold
1 seller · 0% of sales under a 10b5-1 plan
Hongchang International insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Hongchang International Co., Ltd insiders sold a net $1.8K of stock across 3 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 24, 2026.
- The trade is 0.0% of the 62,243,084 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director Lin Zhenzhu sold about $1.1K of HCIL on Jun 25, 2026, the largest insider sale at the company on our record.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 23, 2026.
- The trade is 0.0% of the 62,253,082 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director Lin Zhenzhu sold about $550 of HCIL on Jun 24, 2026, the largest insider sale at the company on our record.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.0% of the 62,258,082 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director Lin Zhenzhu sold about $174 of HCIL on Jun 23, 2026, the largest insider sale at the company on our record.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.8K over 180 days
-$1.8K of it by a 10%+ holder
more than 62% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+7.1% year over year
below 58% of Medical Devices
Margin
-16.5% net margin
more than 50% of Medical Devices
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 14.7 days to cover · settled 2026-09-30
the lowest in Medical Devices
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch HCIL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-97.6%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HCIL: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in HCIL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HCIL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.8K sold by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
HCIL financials
Revenue growth
+7.1%
XBRL, annual
Net margin
-16.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$18.2M
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM HCIL
| FY Dec 2024 | $2.9M |
| FY Dec 2023 | $2.7M |
| FY Dec 2022 | $79.0K |
| FY Dec 2021 | n/a |
| FY Dec 2020 | $222.7K |
| Dec 2025 | $4.0M |
| Sep 2025 | $3.5M |
| Jun 2025 | $3.8M |
| Mar 2025 | $6.9M |
| Dec 2024 | $46.4K |
| Sep 2024 | $820.6K |
| Jun 2024 | $2.0M |
| Mar 2024 | $18.2K |
At each fiscal year end
Single quarter
Net margin, TTM
+13.7%
net income over revenue, 2025-01-01 to 2025-12-31
Net margin, TTM HCIL
| FY Dec 2024 | n/a |
| FY Dec 2023 | -14.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | +7.6% |
| Sep 2025 | +5.7% |
| Jun 2025 | +13.0% |
| Mar 2025 | +21.8% |
| Dec 2024 | n/a |
| Sep 2024 | -7.4% |
| Jun 2024 | -3.3% |
| Mar 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.2M
operating cash flow minus capex, 2025-01-01 to 2025-12-31
Free cash flow, TTM HCIL
| FY Dec 2024 | -$11.4M |
| FY Dec 2023 | -$39.8M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | -$621.2K |
| Sep 2025 | -$511.6K |
| Jun 2025 | -$365.4K |
| Mar 2025 | $2.6M |
| Dec 2024 | $2.2M |
| Sep 2024 | -$4.2M |
| Jun 2024 | -$3.2M |
| Mar 2024 | -$6.1M |
At each fiscal year end
Single quarter
Debt to equity
0.17x
long-term 2025-12-31 plus current 2025-12-31; equity 2025-12-31
Debt to equity HCIL
| FY Dec 2024 | 0.18x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.18x |
| Sep 2024 | 0.16x |
| Jun 2024 | 0.15x |
| Mar 2024 | 0.15x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.30x
TTM operating cash flow over long-term 2025-12-31 plus current 2025-12-31
Cash flow to debt HCIL
| FY Dec 2024 | -1.08x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | 0.30x |
| Sep 2025 | -0.31x |
| Jun 2025 | -0.24x |
| Mar 2025 | -0.66x |
| Dec 2024 | -1.08x |
| Sep 2024 | -0.42x |
| Jun 2024 | -0.55x |
| Mar 2024 | 0.29x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.2%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on equity HCIL
| FY Dec 2024 | n/a |
| FY Dec 2023 | -1.9% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | +6.2% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -0.5% |
| Jun 2024 | -1.6% |
| Mar 2024 | -0.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.1%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on assets HCIL
| FY Dec 2024 | n/a |
| FY Dec 2023 | -0.9% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | -104.3% |
| Dec 2025 | +4.1% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -0.4% |
| Jun 2024 | -1.0% |
| Mar 2024 | -1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+5.3%
operating income after a 9.0% effective tax rate, over long-term 2025-12-31 plus current 2025-12-31 plus average of 2024-12-31 and 2025-12-31 minus cash
Return on invested capital HCIL
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | +5.3% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.1%
operating income (EBIT proxy) over average of 2024-12-31 and 2025-12-31 minus current liabilities
Return on capital employed HCIL
| FY Dec 2024 | n/a |
| FY Dec 2023 | -1.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | +5.1% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -0.5% |
| Jun 2024 | -1.3% |
| Mar 2024 | -1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
9.67x
close 2026-10-26 over four quarters of diluted EPS, 2025-01-01 to 2025-12-31
P/E, trailing HCIL
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 77.78x |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | 237.87x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$9.6M
market value at close 2026-10-26 on 2026-02-11 shares, plus long-term 2025-12-31 plus current 2025-12-31, minus cash 2025-12-31
Enterprise value HCIL
| FY Dec 2024 | $59.8M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | $80.6M |
| Sep 2025 | $49.9M |
| Jun 2025 | $7.0M |
| Mar 2025 | $93.9M |
| Dec 2024 | $59.8M |
| Sep 2024 | $146.3M |
| Jun 2024 | $109.4M |
| Mar 2024 | $120.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+38.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield HCIL
| FY Dec 2024 | -21.3% |
| FY Dec 2023 | -22.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | +1.6% |
| Sep 2025 | +9.2% |
| Jun 2025 | +141.8% |
| Mar 2025 | -3.0% |
| Dec 2024 | -21.3% |
| Sep 2024 | -9.8% |
| Jun 2024 | -9.1% |
| Mar 2024 | -2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing HCIL
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
| Mar 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2024-12 | 2023-12 | 2022-12 | 2021-12 | |
|---|---|---|---|---|
| Revenue | $2.9M | $2.7M | $79.0K | $96.5K |
| Gross profit | $181.6K | $69.4K | $51.6K | $66.2K |
| Operating income | -$383.3K | -$469.6K | -$240.0K | -$162.8K |
| Net income | -$472.4K | -$378.8K | -$240.0K | -$163.0K |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating cash flow | -$7.3M | $750.5K | -$225.8K | -$141.1K |
| Cash | $240.6K | $895.7K | $3.1K | $4.3K |
| Long-term debt | $6.6M | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
HCIL Stock Sonar score 5/7 axes
Find similar shapesCompareHCIL ranks highest on risk and compliance (99th percentile) and financial health (69th), and lowest on insider conviction (31st), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HCIL filings, in plain words
Are Hongchang International insiders buying or selling HCIL?
In the 180 days to 2026-10-28, Hongchang International insiders were net sellers, a net $1.8K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Hongchang International insiders were net sellers of HCIL, a net $1.8K across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $1.8K, came from a holder of 10% or more rather than an officer or director. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
